Press Release
ACI quantitative robot-The power of reading the trends
In 1962, Everett-Rogers proposed the theory of innovative diffusion, designed to explain how, why, and how quickly new ideas and technologies were spread. The theory explains how a product or technology gains momentum and spreads across a specific population over time. The end result is that people apply a product, technology, or idea. One of the key implications is that the application of a new technology in the population does not occur simultaneously. Instead, certain people and groups are more likely to apply technology at different times, consistent with specific psychological and social characteristics. There are five established applicationcategories for new ideas or products. These categories are defined below.
A The Innovator. “Innovators are adventurous and willing to take the risks. They fundamentally wanted to be the first person to try something new. Their goal is to explore new technologies or innovation and to find opportunities to be drivers of change. 」
B Early App. “Once the benefits of a new innovation start to become obvious, early apps are eager to try. Early apps bought new technology to achieve revolutionary breakthroughs that gave them a huge competitive advantage in their industry. They like to gain more advantages than their peers, and they seem to have the time and money to invest. 」
C Early majority. “The early majority of the mainstream usually focused on innovation in solving specific problems. They look for complete products that are fully tested, adhere to industry standards, and are used by others they know in the industry. They are looking for gradual, proven ways to do what they are already doing. 」
D Later majority. “The late most are risk aversion, applying only new innovations to avoid the embarrassment of being left behind. 」
E The Times. “The outdated people stick to the end. They valued traditional methods of doing things and refused to apply new technologies until they were eliminated by previous systems and forced to do it. 」
Bitcoin has captured the human imagination. Bitcoin’s story is perhaps more tempting than any previous high-tech innovation. It brings the most cutting-edge innovation to one of the foundations of mankind: currency. Given the possibility of revolutionizing such a fundamental concept, Bitcoin underwent several speculative cycles in its brief history. However, it would be a serious mistake to use these cycles as grounds for denying Bitcoin. These cycles are a well-understood psychological phenomenon caused by man’s fascination with new things. Moreover, any excessive emphasis on foam is to see the trees without the forest. Because, in just 12 years, Bitcoin has grown to 135 million users worldwide, with a faster application rate than the Internet, mobile phone, or virtual banking tools, namely PayPal, in the comparable period. At the current application rate, Bitcoin will reach 1 billion users in four years. Bitcoin, like all previous innovative technologies, is following a predictable and transparent application curve, although accelerating.
Such an incremental user base, the dividend period retained to us ordinary people about how long still?
Which track should we choose during the dividend period, and what can we can and do on this track?
These will be left for everyone to sink down to think;
For me personally, why I choose quantitative trading this derivative as a long-term development track, why I choose ACI quantitative robot, below I explain this question from two aspects.
First, the above mentioned Bitcoin development rate and user growth base, then for this market must be more and more user growth base, because this is the market of mankind, is Bitcoin’s original design concept —— decentralization, in the future, more and more people will enter the huge market derived from the digital currency such as bitcoin, Ethereum; the longer time period, one year, two years or five years, this cycle youcan grasp the number of your wealth appreciation (the biggest wealth);
Second, the first thing new users enter the market must face the secondary market, retained in the secondary market will learn currency speculation and trading, so what is the biggest difference between quantitative and labor? To enter the secondary market to do trading, the first is to learn mathematics, physics and chemistry, the second is anti-humanity, to face and accept the market of every market fluctuations, the third is to establish a set of their own trading system and resolutely implement. These three points seem simple, but need the hard conditions: 1, talent; 2, systematic learning and combat; 3,5 or even over 10 years of full-time experience; otherwise why there has been a saying: one profit, two draws, two losses and seven losses. Ask, if every user can make money in the digital money market, where does the money come from? And quantitative trading it is more suitable for ordinary players, it also has a scientific name called algorithm trading, it will replace artificial strategy, with mathematical models and scientific strategy, to achieve a certain conditions, but its profit is a stable long-term absolute value, rather than the short term of wealth; because each of us enter the digital currency secondary market, the original intention is to improve life, achieve wealth growth, increase the happiness index;
Third, why do you choose the ACI quantitative robot as a tool to fry the currency?
1. Select any product to make a comparison, especially the financial industry; here put forward a core: withdrawal rate is linked to risk, and the secondary market price of digital currency fluctuates greatly, a careless will be a large withdrawal, so we choose the product is not its return rate, but two products, product recovery rate is 100%, and 50%, product 20 year rate is 70%, and the withdrawal rate is 10%, the choice is only product 2;
2. Fund utilization rate, not just play finance, as long as you do business you will understand that the nature of business is not related to fund utilization, the greater your capital utilization proves that the more you can do, the more pipeline to profit; (those who play Martin strategy)
3. The concept reflected by the ACI quantitative robot is also consistent with the personal development ideal, It is free and continuously updated and optimized for life, Of course there is no free lunch, After all, everything takes costs, It charges a small transaction fee, To mark 99.99% of the various products on the current market, All exceptions are the lowest 20% profit withdrawals, Take an example here, If 10,000 u profit 1,000 u, Excluding withdrawal servants and exchange fees, Only over 700 u, came up with While the same ACI quantized robot profits 1,000 u, with 10,000 u Remove fees, Final hand 935-940u;
4. API technology interface of trading platform, do quantitative is a core is security and stability, as the three head compliance trading platform —— currency network, I think I don’t need me to introduce, whether from the user base, trading depth or technical security, is the best choice, after all, security and stability is not what we want;
Simply summary, quantification is actually statistics
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Dubai, United Arab Emirates, 13th Mar 2026 – ForexBrokers.Live is changing the way traders approach MetaTrader 4 (MT4) and MetaTrader 5 (MT5) platforms. The platform provides forex traders with essential tools, expert insights, and comprehensive guides to make informed decisions when choosing between these popular trading platforms.
MT4 has long been the go-to platform for forex traders, valued for its simplicity and reliability. Meanwhile, MT5 takes trading to the next level, offering additional features for more advanced traders, such as access to a wider range of financial instruments and enhanced charting capabilities. ForexBrokers.Live is committed to helping traders understand these platforms and how they can be used to maximize success in the forex market.
Empowering Traders with Knowledge
ForexBrokers.Live provides easy-to-understand guides that break down the complexities of both MT4 and MT5. The platform doesn’t just explain how to download and set up these platforms, it also offers expert reviews, broker comparisons, and practical tips on using advanced tools effectively. Whether you’re a beginner or an experienced trader, ForexBrokers.Live ensures you have the resources to choose the right broker and platform.
Choosing the Right Broker
Selecting the right broker is as important as choosing the right platform. ForexBrokers.Live makes this process easier by comparing brokers that support MT4 and MT5, highlighting their unique features, spreads, execution speeds, and customer support. This helps traders find the best-suited broker for their needs.
The platform goes beyond platform usage to offer in-depth broker reviews, ensuring traders are well-equipped to navigate the forex market confidently. ForexBrokers.Live also regularly updates its content, so users always have the latest information on brokers and platform features.
Looking Forward
ForexBrokers.Live continues to evolve to meet the growing needs of the trading community. The platform plans to expand its content with more detailed guides, updated reviews, and new features designed to keep traders informed and ready for the market’s challenges.
About ForexBrokers.Live
ForexBrokers.Live is a dedicated resource for forex traders, offering comprehensive guides, expert reviews, and broker comparisons for MetaTrader 4 (MT4) and MetaTrader 5 (MT5). With a focus on clarity and practicality, ForexBrokers.Live helps traders of all levels make informed decisions and choose the best platforms and brokers for their needs.
Media Contact
Organization: ForexBrokers.Live
Contact Person: Manish
Website: https://forexbrokers.live
Email: Send Email
City: Dubai
Country:United Arab Emirates
Release id:42570
The post ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC
Export, PA, United States, 13th Mar 2026 – The upcoming episode of Now We Know! with Steve Guttenberg, airing March 14, 2026 at 1pm ET on CNBC will feature FS-Elliott, a company specializing in the design and manufacturing of high-performance centrifugal air and gas compressors.
The segment provides viewers with a behind-the-scenes look at the engineering and precision required to produce industrial equipment that supports manufacturing, energy production, and critical infrastructure worldwide. Through advanced technology and meticulous design, FS-Elliott’s compressors help power operations across a wide range of industries.
From reliability and efficiency to long-term performance, the episode highlights the role that specialized equipment plays in keeping industrial systems running smoothly.
By showcasing FS-Elliott’s work, Now We Know! sheds light on the often-unseen technologies that support modern industry. The series continues its mission to reveal the innovation and expertise behind the systems that drive everyday life.
About Now We Know!
Hosted by actor, author, and businessman, Steve Guttenberg, this unique platform inspires the next generation of knowledge seekers and viewers around the country. Each episode features up to four industry experts who provide their own unique perspective on the topic at hand via a 6-8–minute segment produced by our team, bringing a fresh look at interesting narratives, moderated by the one and only Steve Guttenberg.
Learn more at NowWeKnowTV.com
About FS-Elliott Co., LLC
FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air and gas compressors, with operations in over 90 countries. For over 60 years, FS-Elliott has combined a commitment to quality with advanced technology, enabling our customers to increase productivity and lower system operating costs. For more information, visit www.fs-elliott.com.
For more details, contact:
Now We Know! with Steve Guttenberg
(877) 546-9995
feature@nowweknowtv.com
SOURCE Now We Know! with Steve Guttenberg
All images courtesy of Now We Know! with Steve Guttenberg
Media Contact
Organization: Now We Know!with Steve Guttenberg
Contact Person: Media Relations
Website: https://nowweknowtv.com/
Email: Send Email
Contact Number: +18775469995
City: Export
State: PA
Country:United States
Release id:42579
The post FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.
The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.
More information about Desidustat Tablets and Renal Anaemia
As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.
There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.
Desidustat Tablets have been approved for marketing in India.
CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.
The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6
2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015
3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)
4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
ForexBrokers.Live: Simplifying MT4 and MT5 for Forex Traders
FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release7 days ago
Tony Swantek Expands His Entrepreneurial Legacy Across Finance, Blockchain, and National Business Services
-
Press Release1 week ago
CVMR and BITEC Establish Joint Venture CVMR R.D. Congo S.A.R.L. to Advance Exploration and In-Country Refining of Strategic Minerals
-
Press Release1 week ago
Cancos Tile and Stone Introduces the CTS Pro plus Collection: A New Professional-Grade Porcelain Tile Series Designed for Builders, Contractors, and Designers
-
Press Release7 days ago
Usethebitcoin (UTB) Strengthens Position as a Leading Guide for Sending Crypto Remittances Globally
-
Press Release7 days ago
Techysquad Highlights Shift Toward Long-Term SEO to Combat Rising Customer Acquisition Costs
-
Press Release1 week ago
Sonoma Manufactured Homes Expands Turnkey Small Home and ADU Installation Services Across Sonoma County
-
Press Release1 week ago
Industry Disruption – IKAPE Unveils K2 PRO Defining Professional Standards for the Mobile Cafe
-
Press Release7 days ago
Indian Contemporary Artist Gautam Mazumdar Stranded in Dubai Amid Escalating War Tensions